These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15558057)

  • 1. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.
    Moschetta A; Bookout AL; Mangelsdorf DJ
    Nat Med; 2004 Dec; 10(12):1352-8. PubMed ID: 15558057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New targets in and potential treatments for cholesterol gallstone disease.
    Doggrell SA
    Curr Opin Investig Drugs; 2006 Apr; 7(4):344-8. PubMed ID: 16625821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the FXR the fix for cholesterol gallstone disease?
    Juran BD; Lazaridis KN
    Hepatology; 2005 Jul; 42(1):218-21. PubMed ID: 15962294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
    Wang HH; Portincasa P; Mendez-Sanchez N; Uribe M; Wang DQ
    Gastroenterology; 2008 Jun; 134(7):2101-10. PubMed ID: 18442485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.
    Chignard N; Mergey M; Barbu V; Finzi L; Tiret E; Paul A; Housset C
    Hepatology; 2005 Sep; 42(3):549-57. PubMed ID: 16037943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the Hypoxia Inducible Factor 1α Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones.
    Asai Y; Yamada T; Tsukita S; Takahashi K; Maekawa M; Honma M; Ikeda M; Murakami K; Munakata Y; Shirai Y; Kodama S; Sugisawa T; Chiba Y; Kondo Y; Kaneko K; Uno K; Sawada S; Imai J; Nakamura Y; Yamaguchi H; Tanaka K; Sasano H; Mano N; Ueno Y; Shimosegawa T; Katagiri H
    Gastroenterology; 2017 May; 152(6):1521-1535.e8. PubMed ID: 28088462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Constitutive Androstane Receptor Prevents Cholesterol Gallstone Formation.
    Cheng S; Zou M; Liu Q; Kuang J; Shen J; Pu S; Chen L; Li H; Wu T; Li R; Li Y; Jiang W; Zhang Z; He J
    Am J Pathol; 2017 Apr; 187(4):808-818. PubMed ID: 28283178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts.
    He J; Nishida S; Xu M; Makishima M; Xie W
    Gastroenterology; 2011 Jun; 140(7):2095-106. PubMed ID: 21354151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothyroidism Increases Cholesterol Gallstone Prevalence in Mice by Elevated Hydrophobicity of Primary Bile Acids.
    Kube I; Tardio LB; Hofmann U; Ghallab A; Hengstler JG; Führer D; Zwanziger D
    Thyroid; 2021 Jun; 31(6):973-984. PubMed ID: 33231505
    [No Abstract]   [Full Text] [Related]  

  • 10. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice.
    Lukovac S; Los EL; Stellaard F; Rings EH; Verkade HJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G520-31. PubMed ID: 19608735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption.
    Jung D; Inagaki T; Gerard RD; Dawson PA; Kliewer SA; Mangelsdorf DJ; Moschetta A
    J Lipid Res; 2007 Dec; 48(12):2693-700. PubMed ID: 17823457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization.
    Uppal H; Zhai Y; Gangopadhyay A; Khadem S; Ren S; Moser JA; Xie W
    Hepatology; 2008 Apr; 47(4):1331-42. PubMed ID: 18318438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile salt excretory pump: biology and pathobiology.
    Suchy FJ; Ananthanarayanan M
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
    Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
    Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis.
    Lammert F; Wang DQ; Hillebrandt S; Geier A; Fickert P; Trauner M; Matern S; Paigen B; Carey MC
    Hepatology; 2004 Jan; 39(1):117-28. PubMed ID: 14752830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice.
    Wittenburg H; Lyons MA; Li R; Churchill GA; Carey MC; Paigen B
    Gastroenterology; 2003 Sep; 125(3):868-81. PubMed ID: 12949731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse.
    Wang DQ; Tazuma S; Cohen DE; Carey MC
    Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G494-502. PubMed ID: 12748061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
    Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
    Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.